- Report
- November 2023
- 272 Pages
Global
From €3249EUR$3,570USD£2,785GBP
- Book
- April 2024
- 448 Pages
- Book
- December 2023
- 864 Pages
- Book
- April 2023
- 128 Pages
- Book
- April 2023
- 176 Pages
- Book
- November 2022
- 208 Pages
- Book
- September 2021
- 304 Pages
- Book
- October 2020
- 600 Pages
- Book
- December 2019
- 432 Pages
- Book
- November 2019
- 432 Pages
- Book
- January 2019
- 600 Pages
- Book
- March 2018
- 112 Pages
- Book
- January 2016
- 952 Pages
- Book
- June 2024
- 496 Pages
- Book
- December 2019
- 432 Pages
- Book
- November 2019
- 432 Pages
€2204EUR$2,594USD£1,956GBP
- Book
- October 2023
North America

Myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is a form of hematological malignancy, which is a cancer of the blood or bone marrow. Myeloma is the second most common type of hematological malignancy, after lymphoma. Symptoms of myeloma include bone pain, anemia, frequent infections, and kidney problems. Treatment options include chemotherapy, radiation therapy, stem cell transplant, and targeted therapy.
The myeloma market is a subset of the hematology market, which is a large and growing market. The market is driven by the increasing prevalence of hematological malignancies, as well as advances in treatment options. The market is expected to continue to grow in the coming years, as new treatments are developed and more patients are diagnosed.
Some companies in the myeloma market include Bristol-Myers Squibb, Celgene, Novartis, and Takeda. Show Less Read more